NYSE: EWEdwards Lifesciences

    Edwards Lifesciences Q3 2026 Results: Net Income $308 Million on Revenue of $1.72 Billion

    • US stocks
    • Earnings
    • Health Care
    Stainless steel surgical clamps and forceps laid out on a green surgical drape
    آرمین, via Wikimedia Commons (CC0). Illustrative image.

    Edwards Lifesciences (NYSE: EW) reported GAAP revenue of $1.72 billion and GAAP net income of $307.5 million attributable to the company for the third quarter of 2026, it said on 4 Nov 2026. Diluted EPS was $0.53 on a GAAP basis. Adjusted EPS, a company-defined measure that excludes items such as litigation expenses and an impairment charge, was $0.80.

    Key highlights

    • Revenue (GAAP): $1.72 billion, up 10.5% YoY and down 1.5% QoQ
    • Operating income (GAAP): $299.1 million, down 2.6% YoY and down 41.7% QoQ
    • Net income (GAAP, attributable to the company): $307.5 million, up 5.6% YoY and up 27.1% QoQ
    • Diluted EPS (GAAP): $0.53, up 6.0% YoY and up 26.2% QoQ
    • Adjusted EPS (company-defined, excludes certain items): $0.80

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue1,715.51,553.1+10.5%1,741.0-1.5%
    299.1307.1-2.6%513.2-41.7%
    307.5291.1+5.6%241.9+27.1%
    Diluted EPS ($)0.530.50+6.0%0.42+26.2%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table sets third-quarter 2026 GAAP results against the same quarter of 2025 and the second quarter of 2026. Revenue rose 10.5% from a year earlier, to $1.72 billion from $1.55 billion, while operating income fell 2.6%, to $299.1 million from $307.1 million. The operating margin was 17.4%, against 19.8% a year earlier.

    Net income attributable to the company rose 5.6% from a year earlier, to $307.5 million from $291.1 million. From the second quarter of 2026, revenue fell 1.5% and net income rose 27.1%, to $307.5 million from $241.9 million. The net income margin was 17.9%, against 18.7% a year earlier.

    Adjusted figures exclude items the company names

    The company also reports adjusted measures, which it describes as non-GAAP. Its adjusted diluted EPS of $0.80 excludes items such as an impairment of intangible and long-lived assets of $220.2 million and a net insurance recovery of $12.7 million from litigation expenses.

    On the adjusted basis, gross profit margin was 78.7%, against 77.9% a year earlier, and operating profit margin was 30.3%, against 27.5%. The company also named acquisition contract termination costs of $8.7 million among its adjustments.

    TMTT sales rose 44.0%, TAVR 8.0% and Surgical 2.5%

    TAVR sales were $1.24 billion, up 8.0% from a year earlier, or 8.8% on a constant currency basis, a non-GAAP measure that excludes currency effects and newly acquired products. The company said procedure growth benefited from a heightened focus on TAVR and data on proactive disease management. It also said CMS released the final, updated national coverage determination for TAVR during the quarter.

    TMTT sales were $207 million on the company's adjusted basis, which excludes $2.9 million of Implantable Heart Failure Management revenue. That was up 44.0%, or 45.6% on a constant currency basis. Surgical sales were $264.4 million, up 2.5%, or 2.8% on a constant currency basis.

    Outlook raised for 2026 sales and EPS

    The company now expects 2026 total company sales growth of approximately 11.5%, up from a previous range of 10% to 11%. The TAVR sales growth outlook is now 9.0% to 9.5%, previously 8% to 9%.

    The TMTT sales outlook is now $780 to $790 million, previously $760 to $780 million, and adjusted EPS is now $2.97 to $3.05, previously $2.95 to $3.05. It said it reaffirmed mid-single-digit growth guidance for Surgical. For the fourth quarter of 2026, the company projects total sales of $1.67 to $1.75 billion and adjusted EPS of $0.61 to $0.69. It also said adjusted gross profit margin is expected at the lower end of its full-year 78% to 79% guidance, citing currency effects through its hedging program.

    Inference

    The weighted-average diluted share count was 577.6 million in the quarter, against 585.7 million a year earlier. Through the third quarter, the company said it had bought back roughly $700 million of stock, and about $1.3 billion remains under its authorization.

    The release gives no dividend, operating cash flow or free cash flow figure for the quarter. The next dated step it gives is the fourth quarter of 2026 outlook.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts